<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01779908</url>
  </required_header>
  <id_info>
    <org_study_id>CDA grant no OG-3-12-3681-CG</org_study_id>
    <secondary_id>B12-12-1095</secondary_id>
    <nct_id>NCT01779908</nct_id>
  </id_info>
  <brief_title>Role of Vitamin D in the Prevention and Treatment of Diseases Associated With Insulin Resistance</brief_title>
  <acronym>VIDIR</acronym>
  <official_title>Role of Vitamin D in the Prevention and Treatment of Diseases Associated With Insulin Resistance</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>CHU de Quebec-Universite Laval</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Canadian Diabetes Association</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Laval University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Fonds de la Recherche en Santé du Québec</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>CHU de Quebec-Universite Laval</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Prospective, randomized and placebo-controlled 6-month trial of vitamin D supplementation in&#xD;
      130 Caucasian and vitamin D-deficient men and women aged 25 years and over. Participants will&#xD;
      have abdominal obesity and at least one factor associated with insulin resistance.&#xD;
      Participants will be randomized by sex, BMI and age. The primary aim is to compare the effect&#xD;
      of daily vitamin D3 (cholecalciferol, 5000 IU) vs. placebo for 6 mo on insulin sensitivity&#xD;
      (M-value by the gold standard method, the euglycemic hyperinsulinemic clamp). Secondary aims&#xD;
      are to evaluate the effects of vitamin D3 vs. placebo on other indices of glucose metabolism,&#xD;
      the lipid profile, blood pressure and anthropometric measurements. Questionnaires on physical&#xD;
      activity and sunlight exposure, and a food frequency questionnaire will be administered at 0&#xD;
      and 6 mo to adjust for confounding factors. At 0 and 6 mo, changes in serum 25(OH)D will be&#xD;
      correlated with changes in blood markers associated with insulin sensitivity [hs-CRP,&#xD;
      inflammatory cytokines (IL-6 and TNF-alpha), adiponectin, leptin, total and undercarboxylated&#xD;
      osteocalcin].&#xD;
&#xD;
      This research project intends to test 2 major hypotheses: (1) that vitamin D deficiency plays&#xD;
      a causal role in the pathogenesis of insulin resistance in humans; and (2) that vitamin D&#xD;
      increases insulin sensitivity.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Part 1: Prospective, randomized and placebo-controlled 6-month trial of vitamin D&#xD;
      supplementation in 130 Caucasian and vitamin D-deficient [serum 25(OH)D ≤55 nM] men and women&#xD;
      aged 25 years and over with a BMI ≤40 kg/m2. Participants will have abdominal obesity&#xD;
      (increased waist circumference of at least 102 cm for men and 88 cm for women) and at least&#xD;
      one factor associated with insulin resistance, namely: (1) serum triglyceride levels of at&#xD;
      least 1.7 mmol/L or treated dyslipidemia; (2) prediabetes or untreated type 2 diabetes (HbA1c&#xD;
      &gt;=5.6% or fasting glucose &gt;=5.6 mmol/L or glucose 2h post OGTT &gt;=7.8 mmol/L); (3) first&#xD;
      degree relative with type 2 diabetes; (4) history of gestational diabetes. Participants will&#xD;
      be randomized according to sex, BMI (&lt;30 kg/m2 vs. 30 kg/m2 and over) and age (&lt; or &gt;=50&#xD;
      years old). The primary aim is to compare the effect of daily vitamin D3 (cholecalciferol,&#xD;
      5000 IU) vs. placebo for 6 mo on insulin sensitivity (M-value by the gold standard method,&#xD;
      the euglycemic hyperinsulinemic clamp). Secondary aims are to evaluate the effects of vitamin&#xD;
      D3 vs. placebo on other indices of glucose metabolism (fasting glucose, 2-h plasma glucose&#xD;
      post OGTT, HbA1c, insulin sensitivity index (HOMA-IS using fasting glucose and insulin),&#xD;
      insulin secretion index (HOMA-B using fasting glucose and C-peptide), insulinogenic index&#xD;
      [(C-peptide at 30 min post OGTT - C-peptide at 0 min)/(glucose at 30 min post OGTT - glucose&#xD;
      at 0 min)] and disposition index (insulinogenic index x M-value)), the lipid profile, blood&#xD;
      pressure and anthropometric measurements (weight, waist and hip circumference, bioimpedance&#xD;
      analysis). Questionnaires on physical activity and sunlight exposure, and a food frequency&#xD;
      questionnaire will be administered at 0 and 6 mo to adjust for confounding factors. At 0 and&#xD;
      6 mo, biochemical markers associated with insulin sensitivity will be measured (point 2).&#xD;
&#xD;
      Part 2: Mechanistic studies comparing, before and after vitamin D3 supplementation, changes&#xD;
      in serum 25(OH)D with changes in blood markers associated with insulin sensitivity [hs-CRP,&#xD;
      inflammatory cytokines (IL-6 and TNF-alpha), adiponectin, leptin, total and undercarboxylated&#xD;
      osteocalcin].&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>January 2013</start_date>
  <completion_date type="Actual">June 2020</completion_date>
  <primary_completion_date type="Actual">June 2, 2017</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in peripheral insulin sensitivity assessed by the euglycemic-hyperinsulinemic clamp between placebo and vitamin D groups</measure>
    <time_frame>0 and 6 months</time_frame>
    <description>M-value</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change in peripheral insulin sensitivity assessed by the euglycemic-hyperinsulinemic clamp between placebo and vitamin D groups</measure>
    <time_frame>0 and 6 months</time_frame>
    <description>M/I ratio</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change in insulin sensitivity indice assessed by fasting- and oral glucose tolerance test between placebo and vitamin D groups</measure>
    <time_frame>0 and 6 months</time_frame>
    <description>HOMA2%S</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in insulin sensitivity indice assessed by fasting- and oral glucose tolerance test between placebo and vitamin D groups</measure>
    <time_frame>0 and 6 months</time_frame>
    <description>Matsuda index</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in insulin secretion indice between placebo and vitamin D groups</measure>
    <time_frame>0 and 6 months</time_frame>
    <description>area under the curve for C-peptide</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in insulin secretion indice between placebo and vitamin D groups</measure>
    <time_frame>0 and 6 months</time_frame>
    <description>HOMA2-B</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in insulin secretion indice between placebo and vitamin D groups</measure>
    <time_frame>0 and 6 months</time_frame>
    <description>insulinogenic index</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in B-cell function between placebo and vitamin D groups</measure>
    <time_frame>0 and 6 months</time_frame>
    <description>Disposition index</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in metabolic markers between placebo and vitamin D groups</measure>
    <time_frame>0 and 6 months</time_frame>
    <description>HbA1c</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in metabolic markers between placebo and vitamin D groups</measure>
    <time_frame>0 and 6 months</time_frame>
    <description>Fasting glucose</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in metabolic markers between placebo and vitamin D groups</measure>
    <time_frame>0 and 6 months</time_frame>
    <description>2h glucose post-OGTT</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in anthropometry between placebo and vitamin D groups</measure>
    <time_frame>0 and 6 months</time_frame>
    <description>Weight</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in anthropometry between placebo and vitamin D groups</measure>
    <time_frame>0 and 6 months</time_frame>
    <description>BMI</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in anthropometry between placebo and vitamin D groups</measure>
    <time_frame>0 and 6 months</time_frame>
    <description>waist circumference</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in anthropometry between placebo and vitamin D groups</measure>
    <time_frame>0 and 6 months</time_frame>
    <description>hip circumference</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in anthropometry between placebo and vitamin D groups</measure>
    <time_frame>0 and 6 months</time_frame>
    <description>fat mass by bioimpedance analysis</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in blood pressure between placebo and vitamin D groups</measure>
    <time_frame>0 and 6 months</time_frame>
    <description>Systolic and diastolic blood pressure</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">96</enrollment>
  <condition>Vitamin D-deficient</condition>
  <condition>Insulin-resistant</condition>
  <arm_group>
    <arm_group_label>Vitamin D supplementation</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>5000 IU of vitamin D3 for 6 months</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo pill for 6 months</description>
  </arm_group>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Vitamin D</intervention_name>
    <arm_group_label>Vitamin D supplementation</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Caucasian men and women&#xD;
&#xD;
          -  ≥25 yrs&#xD;
&#xD;
          -  vitamin D deficiency [serum 25(OH)D concentration ≤55 nM]&#xD;
&#xD;
          -  Abdominal obesity (waist circumference &gt;=102 cm for men and &gt;=88 cm for women) AND at&#xD;
             least one factor associated with insulin resistance: (1) fasting serum triglycerides&#xD;
             &gt;=1.7 mmol/L or treated dyslipidemia; (2) prediabetes or untreated type 2 diabetes&#xD;
             (HbA1c &gt;=5.6% or fasting glucose &gt;=5.6 mmol/L or 2h glucose post OGTT &gt;=7.8 mmol/L);&#xD;
             (3) first degree relative with type 2 diabetes; (4) history of gestational diabetes.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Type 2 diabetes under drug therapy&#xD;
&#xD;
          -  HbA1c &gt;7%&#xD;
&#xD;
          -  BMI &gt;40 kg/m2&#xD;
&#xD;
          -  pregnancy or breast-feeding;&#xD;
&#xD;
          -  medication influencing vitamin D or glucose metabolism in the last 3 mo&#xD;
&#xD;
          -  regular consumption of supplements containing &gt;400 IU/d of vitamin D3 over the last 2&#xD;
             mo;&#xD;
&#xD;
          -  renal insufficiency (creatinine clearance &lt;60 ml/min);&#xD;
&#xD;
          -  cirrhosis,&#xD;
&#xD;
          -  intestinal malabsorption (bypass surgery, celiac disease, etc);&#xD;
&#xD;
          -  osteoporosis;&#xD;
&#xD;
          -  history of nephrolithiasis;&#xD;
&#xD;
          -  hypercalcemia (&gt;2.6 mM);&#xD;
&#xD;
          -  hypercalciuria (&gt;0.6 fasting urine Ca/creatinine ratio);&#xD;
&#xD;
          -  &gt;5% change in weight in the last 3 mo;&#xD;
&#xD;
          -  diseases affecting glucose metabolism (e.g. hyperthyroidism);&#xD;
&#xD;
          -  pacemaker (for bioimpedance only);&#xD;
&#xD;
          -  inability to provide informed consent and complete questionnaires due to physical or&#xD;
             mental problems.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>25 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Claudia Gagnon, Dr.</last_name>
    <role>Principal Investigator</role>
    <affiliation>CHU de Québec Research Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>CHU de Québec, Laval University Research Center</name>
      <address>
        <city>Quebec city</city>
        <state>Quebec</state>
        <zip>G1V 4G2</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Canada</country>
  </location_countries>
  <verification_date>July 2020</verification_date>
  <study_first_submitted>January 24, 2013</study_first_submitted>
  <study_first_submitted_qc>January 29, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 30, 2013</study_first_posted>
  <last_update_submitted>July 22, 2020</last_update_submitted>
  <last_update_submitted_qc>July 22, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">July 24, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>CHU de Quebec-Universite Laval</investigator_affiliation>
    <investigator_full_name>Claudia Gagnon</investigator_full_name>
    <investigator_title>MD</investigator_title>
  </responsible_party>
  <keyword>Vitamin D supplementation</keyword>
  <keyword>Insulin resistance</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Insulin Resistance</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Vitamin D</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

